The global single cell genome sequencing market size was exhibited at USD 3.31 billion in 2023 and is projected to hit around USD 12.79 billion by 2032, growing at a healthy CAGR of 16.2% from 2023 to 2032.
The global single cell genome sequencing market size was exhibited at USD 3.31 billion in 2023 and is projected to hit around USD 12.79 billion by 2032, growing at a healthy CAGR of 16.2% from 2023 to 2032.
Some of the key trends triggering the market growth are the increasing prevalence of chronic diseases like cancer, diabetes, and arthritis; advanced technology and latest collaborations; and rising geriatric population. In addition, companies are placing greater emphasis on product development, further fueling the market’s expansion.
Request PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.novaoneadvisor.com/report/sample/8365
The growth of the market is being significantly influenced by the notable technological advancements in single-cell genome sequencing (SCGS). For instance, the collaboration between Bio-Rad Laboratories, Inc. and Illumina, Inc., aimed at developing an innovative workflow for SCGS analysis. The successful outcome of this collaboration led to the launch of a cutting-edge SCGS solution. These advanced platforms not only offer intuitive analysis software solutions but are also cost-effective, making them a promising addition to the market. As an advanced technology, this procedure is widely used in a variety of research such as in neurology, immunology, cancer, and other such diseases and medical streams. Medical institutes are leveraging SCGS to enhance their complex microbial ecosystems and multicellular organism diseases. Considering these significant findings, SCGS is anticipated to emerge as a valuable asset in the healthcare sector in the coming years.
The COVID-19 pandemic has had a positive impact on the market. Since 2020 and continuing even after the initial phase after the pandemic subsided, many research institutions conducted research studies regarding the effects of single cell sequencing on cells from a COVID-19-positive patient, revealing crucial insights about both. These research efforts have resulted in continuous advancements in the market, leading to an exponential growth.
What are the unique features of Single Cell Genome Sequencing, in terms of quality and efficiency?
Our Single Cell Genome Sequencing platform boasts unparalleled quality and efficiency. With its ability to resolve genetic information at the single-cell level, it offers unmatched insights into genomic heterogeneity within populations. By isolating individual cells, we ensure minimal contamination and maximize data purity. Our platform excels in detecting rare cell types, enabling unbiased analysis and the discovery of novel subtypes. It achieves high sensitivity and specificity, crucial for identifying low-frequency variants and rare mutations.
Moreover, it efficiently utilizes data by capturing genomic information from individual cells, facilitating comprehensive analyses of cellular heterogeneity. With integrated genomic and transcriptomic analyses, our platform provides quantitative insights into gene expression, chromatin accessibility, and DNA modifications at the single-cell level. Overall, our Single Cell Genome Sequencing platform sets the standard for quality, efficiency, and depth of insight into cellular systems
Key Takeaways:
- North America dominated the regional market in 2023, with a revenue share of 47.88%.
- Asia Pacific is anticipated to grow at the fastest CAGR of 17.5% over the forecast period.
- In terms of product, the instruments segment dominated the market in 2023, with a revenue share of 59.6%.
- This segment is expected to witness the fastest CAGR of 16.2% over the forecast period
- The PCR segment dominated the market in 2023 with a revenue share of 28.17%.
- The fastest-growing technology segment with a CAGR of 17.1% over the forecast period.
- The genomic analysis segment dominated the market in 2023, with a market size of 70.45%.
- The cancer segment dominated the market in 2023 with a revenue share of 36.15%.
- The academic & research laboratories segment dominated the market in 2023, with a revenue share of 73.15%.
- The academic & research laboratories segment dominated the market in 2023, with a revenue share of 73.15%.
- The academic & research laboratories segment dominated the market in 2023, with a revenue share of 73.15%.
- The academic & research laboratories segment dominated the market in 2023, with a revenue share of 73.15%.
Immediate Delivery Available, Get Full Access@ https://www.novaoneadvisor.com/report/checkout/8365
Product Type Insights
In terms of product, the instruments segment dominated the market in 2023, with a revenue share of 59.6%. This dominance can be primarily attributed to the accelerated development and adoption of technologically advanced instruments and solutions, specifically designed to keep pace with the dynamic changes in healthcare technological advancements. This segment is expected to witness the fastest CAGR of 16.2% over the forecast period due to the increased focus of market players on developing and manufacturing these instruments. Such efforts aim to expand their market presence and seize opportunities to enter new markets.
Technology Insights
In terms of technology, the PCR segment dominated the market in 2023 with a revenue share of 28.17%. Due to heavy investments in R&D, PCR is a widely recognized technology when it comes to genome sequencing, highly coveted by market leaders and research institutes. NGS is poised to emerge as the fastest-growing technology segment with a CAGR of 17.1% over the forecast period. This remarkable growth can be attributed to extensive R&D activities and its diverse applications in cancer-related investigations.
Genome sequencing has evolved significantly over the past few years due to constant technological advancements. For instance, in March 2023, researchers at ETH Zurich used a new approach using single-cell genome sequencing to analyze the DNA from two different T-cells that were obtained from the same period. This sequencing data revealed 28 somatic mutations that differentiated the two T-cells and identified any mitochondrial DNA changes. It was inferred that this new method could potentially allow scientists to study various impacts of somatic mutations in a host of diseases.
Workflow Insights
The workflow segment is divided into genomic analysis, single cell isolation, and sample preparation. The genomic analysis segment dominated the market in 2023, with a market size of 70.45%. This dominance can be attributed to the recent surge in funding for research and development capabilities and the widespread adoption of genomic analysis products. As a result, this segment is projected to experience the fastest CAGR of 16.8% during the forecast period.
These recent developments have also created new opportunities for mutation rate quantification, rare cell type identification, and other diagnoses and treatments. Genomic analysis allows comprehensive identification, measurement, and comparison of genomic features like DNA sequence, gene expression, and other regulatory and functional annotations. This analysis allows companies to study cells in depth, ensuring lucrative growth for this segment. For instance, a research publication released on 30th May 2023, showcased how genomic analysis studies have revealed candidate genes associated with milk production and adaptive traits in goat breeds. These findings exemplify the potential and significance of genomic analysis in uncovering valuable insights in diverse fields of research.
Disease Area Insights
The disease area segment is divided into cancer, immunology, prenatal diagnosis, neurobiology, microbiology, and others. The cancer segment dominated the market in 2023 with a revenue share of 36.15%. The increasing prevalence of prostate, colorectal, and breast cancer is projected to generate lucrative opportunities for market growth. Notably, according to the American Cancer Society, cancer ranks as the second leading cause of mortality in the U.S.
With an increase in cancer incidences, there has been a complementary increase in the number of research studies and experiments being conducted. Therefore, rise in cancer incidences is also causing a growth in the SCGS market. For instance, in October 2022, researchers from UBC and the BC Cancer Research Institute conducted cancer-related research, which showed that single cell genome sequencing provided new insights into deadly cancers. The researchers were able to sequence the genomes of individual cells from the biopsies of 158 BC Cancer patients, allowing them to observe the processes of evolution within each individual cell.
Application Insights
The application segment is divided into circulating cells, cell differentiation/reprogramming, genomic variation, subpopulation characterization, and others. The circulating cells segment dominated the market in 2023, with a revenue share of 30.45%. This is due to an increase in clinical application of circulating tumor cells (CTCs) as biomarkers for cancer detection, used as genomic profilers for sequence mutations and other such applications.
CTCs allow blood circulation within the primary tumor and regulate tumor metastasis to fight cancer. Due to increasing R&D opportunities and growing number of research, studies, and clinical trials, the circulating cells segment is forecasted to grow at a significant CAGR of 16.3% over the coming years. For instance, in January 2023, researchers at IIT Delhi worked in collaboration with Fluidigm Corporation, US, to develop an innovative and deep dictionary learning to detect circulating cells in the bloodstream, called unCTC.
The prenatal diagnosis segment is anticipated to grow at the fastest CAGR of 17.2% over the forecast period owing to the increasing number of medical tests and procedures that are performed during pregnancy to detect potential health issues or abnormalities in the developing fetus coupled with higher resolution and accuracy of SCGS compared to traditional sequencing methods.
End-use Insights
The end-use segment is divided into academic & research laboratories, biotechnology & biopharmaceutical companies, clinics, and others. The academic & research laboratories segment dominated the market in 2023, with a revenue share of 73.15%. This growth is attributed to the rise in genomic centers, increase in life science research funding, and growing number of medical colleges and institutions in major regions.
The biotechnology & biopharmaceutical companies segment is anticipated to grow at the fastest CAGR over the forecast period. This is due to the increasing dependency of medical institutions and hospitals on these companies for research access, results, and other equipment and related contingencies. Due to their strong market presence and desire to enter the single-cell genome sequencing market, many biotechnology companies are pursuing different competitive strategies to stretch their lead. As a result, this segment is anticipated to grow significantly.
Ask Here for Customization@ https://www.novaoneadvisor.com/report/customization/8365
Regional Insights
North America dominated the regional market in 2023, with a revenue share of 47.88%. This dominance can be attributed to several factors, including the increasing incidence of cancer and other chronic diseases in the region. In addition, the continuous advancements in technology and research and development efforts by companies in North America have contributed to this lead. Moreover, the rise in the number of genomic clinics in the region has further boosted its position in the market.
Asia Pacific is anticipated to grow at the fastest CAGR of 17.5% over the forecast period. One of the primary drivers of the growth is the rising geriatric population, leading to an increased prevalence of chronic diseases among patients. In addition, the region is anticipated to witness significant advancements in healthcare infrastructure, driven by developing countries’ efforts to boost their economies.
Some of the prominent players in the Single Cell Genome Sequencing Market include:
- Bio-Rad Laboratories
- 10x Genomics
- Novogene
- Fluidigm
- BGI
- Illumina, Inc.
- Oxford Nanopore Technologies
- Pacific Biosciences
- Thermo Fisher Scientific, Inc.
- QIAGEN
- F. Hoffmann-La-Roche Ltd.
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Single Cell Genome Sequencing market.
By Product Type
- Instruments
- Reagents
By Technology
- NGS
- PCR
- qPCR
- Microarray
- MDA
By Workflow
- Genomic Analysis
- Single Cell Isolation
- Sample Preparation
By Disease Area
- Cancer
- Immunology
- Prenatal Diagnosis
- Neurobiology
- Microbiology
- Others
By Application
- Circulating Cells
- Cell Differentiation/Reprogramming
- Genomic Variation
- Subpopulation Characterization
- Others
By End-use
- Academic & Research Laboratories
- Biotechnology & Biopharmaceutical Companies
- Clinics
- Others
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa (MEA)
Immediate Delivery Available | Buy This Premium Research https://www.novaoneadvisor.com/report/checkout/8365
You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333